FourThought Financial LLC Has $484,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

FourThought Financial LLC raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 26.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,670 shares of the pharmaceutical company’s stock after buying an additional 350 shares during the period. FourThought Financial LLC’s holdings in Vertex Pharmaceuticals were worth $484,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Farmers & Merchants Investments Inc. boosted its position in Vertex Pharmaceuticals by 25.0% in the third quarter. Farmers & Merchants Investments Inc. now owns 165 shares of the pharmaceutical company’s stock valued at $48,000 after buying an additional 33 shares in the last quarter. Emfo LLC boosted its position in Vertex Pharmaceuticals by 15.5% in the third quarter. Emfo LLC now owns 254 shares of the pharmaceutical company’s stock valued at $74,000 after buying an additional 34 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its position in Vertex Pharmaceuticals by 1.7% in the third quarter. Sound View Wealth Advisors Group LLC now owns 2,282 shares of the pharmaceutical company’s stock valued at $661,000 after buying an additional 38 shares in the last quarter. Albion Financial Group UT boosted its position in Vertex Pharmaceuticals by 3.0% in the third quarter. Albion Financial Group UT now owns 1,387 shares of the pharmaceutical company’s stock valued at $402,000 after buying an additional 40 shares in the last quarter. Finally, Princeton Global Asset Management LLC boosted its position in Vertex Pharmaceuticals by 0.3% in the third quarter. Princeton Global Asset Management LLC now owns 15,023 shares of the pharmaceutical company’s stock valued at $4,350,000 after buying an additional 40 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ:VRTX opened at $300.64 on Friday. Vertex Pharmaceuticals Incorporated has a 52 week low of $233.01 and a 52 week high of $325.19. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.66 and a current ratio of 4.83. The company has a market capitalization of $77.29 billion, a PE ratio of 23.43, a PEG ratio of 2.54 and a beta of 0.49. The company has a 50 day moving average price of $299.04 and a two-hundred day moving average price of $298.92.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last issued its earnings results on Tuesday, February 7th. The pharmaceutical company reported $3.76 EPS for the quarter, beating the consensus estimate of $3.11 by $0.65. Vertex Pharmaceuticals had a net margin of 37.20% and a return on equity of 27.78%. The firm had revenue of $2.30 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the prior year, the firm earned $3.18 earnings per share. The business’s quarterly revenue was up 11.1% on a year-over-year basis. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 12.44 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Yuchun Lee sold 442 shares of the company’s stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $312.17, for a total value of $137,979.14. Following the completion of the sale, the director now owns 1,875 shares of the company’s stock, valued at $585,318.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Yuchun Lee sold 442 shares of the stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $312.17, for a total transaction of $137,979.14. Following the completion of the sale, the director now owns 1,875 shares of the company’s stock, valued at $585,318.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Stuart A. Arbuckle sold 5,034 shares of the stock in a transaction on Monday, February 27th. The stock was sold at an average price of $287.47, for a total transaction of $1,447,123.98. Following the sale, the chief operating officer now directly owns 56,556 shares of the company’s stock, valued at approximately $16,258,153.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,916 shares of company stock valued at $12,466,970. Corporate insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on VRTX. HC Wainwright boosted their price target on shares of Vertex Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a research report on Wednesday, February 8th. Barclays upped their target price on shares of Vertex Pharmaceuticals from $313.00 to $342.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 8th. StockNews.com started coverage on shares of Vertex Pharmaceuticals in a research report on Thursday. They set a “strong-buy” rating on the stock. Canaccord Genuity Group started coverage on shares of Vertex Pharmaceuticals in a research report on Wednesday, January 18th. They set a “hold” rating and a $311.00 target price on the stock. Finally, Piper Sandler reiterated a “neutral” rating and set a $296.00 target price on shares of Vertex Pharmaceuticals in a research report on Wednesday, February 8th. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $327.10.

Vertex Pharmaceuticals Company Profile

(Get Rating)

Vertex Pharmaceuticals, Inc is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.